Celgene's multiple sclerosis drug succeeds in late-stage trial
May 22, 2017 at 07:54 AM EDT
May 22 (Reuters) - Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study.